extended release bupropion (BUP-XL) tablets (BUP-XL)
Phase 3
extended release bupropion (BUP-XL) tablets (BUP-XL) is one of 36 therapeutic programs targeting Methamphetamine Dependence. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
41 competitors in Methamphetamine Dependence
#DrugCompanyPhaseTrials
1Provigil
NNuvo Research GmbH
Approved
Minipress
PfizerApproved
Abilify
OtsukaApproved
Prometrium
FerringApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Suboxone
IIndivior Inc.
Approved
Campral
FForest Laboratories
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Risperdal
WWim Janssens
Approved
Revia
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]